CT-based assessment of body composition following neoadjuvant chemohormonal therapy in patients with castration-naïve oligometastatic prostate cancer.
Sara SheikhbahaeiDiane K ReyesSteven P RoweKenneth J PientaPublished in: The Prostate (2020)
Our findings showed a significant reduction in muscle mass and an increase in subcutaneous adiposity in men treated with neoadjuvant docetaxel and ADT, more pronounced on the first follow-up scan after completion of neoadjuvant treatment. Body composition parameters were not found to be significant predictors of disease progression in our cohort.
Keyphrases
- body composition
- locally advanced
- rectal cancer
- prostate cancer
- lymph node
- resistance training
- bone mineral density
- computed tomography
- squamous cell carcinoma
- radiation therapy
- radical prostatectomy
- dual energy
- insulin resistance
- image quality
- stem cells
- contrast enhanced
- positron emission tomography
- body mass index
- metabolic syndrome
- adipose tissue
- mesenchymal stem cells
- physical activity
- replacement therapy
- pet ct
- smoking cessation